CX3CR1 as a target for airways inflammation

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 9, 2011, Pages 1139-1142

  Doggrell, Sheila A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Airways inflammation; Asthma; CX3CL1 CX3CR1 axis; FKN AT; Mouse model of asthma

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CX3CR1; DEXAMETHASONE; F 1; FRACTALKINE; FRACTALKINE ANTAGONIST; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; UNCLASSIFIED DRUG;

AIRWAY INFLAMMATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CELL SURVIVAL; DOWN REGULATION; DRUG MECHANISM; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; TH2 CELL;

EID: 80051775128     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.597383     Document Type: Article

References (13)

1. Wills-Karp M. Immunological basis of antigen-induced airway hyperresponsiveness. Ann Rev Immunol 1999;17:255-81
2. Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine (CX3CR1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001;107:1173-81
3. Imai T, Heishima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-30
4. El-Shazly A, Berger P, Girodet P-O, et al. Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma. J Immunol 2006;176:1860-8
5. Rimaniol AC, Till SJ, Garcia G, et al. The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol 2003;112:1139-46
6. Mionnet C, Buatois V, Kanda A, et al. CXCR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med 2010;16:1305-13
7. Cohn L, Homer RJ, Marinov A, et al. Induction of airway mucus production by T helper (TH2) cells: A critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med 1997;186:1737-47
8. Dorgham K, Ghadri A, Hermand P, et al. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 2009;86:903-11
9. Ning W, Li CJ, Kaminski N, et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004;101:14895-900
10. Balabanian K, Foussat A, Dortmuler P, et al. CX3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1419-25
11. McComb JG, Ranganathan M, Liu XH, et al. CX3CL1 up-regulation is associated with recruitment of CX3CR1+ mononuclear phagocytes and T lymphocytes in the lungs during cigarette smoke-induced emphysema. Am J Pathol 2008;173:949-61
12. Wang W, Wang YL, Chen XY, et al. Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep 2011;38:3277-84
13. Bhavsar PK, Sukkar MB, Khosani N, et al. Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB. FASEB J 2008;22:1807-16